Biotechnology Animations – Biotechnology Illustrations

Prolonged Nevirapine In Breast-Fed Babies Prevents HIV Infection But Leads To Drug-Resistant HIV
Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report. But the investigators highlight the proven superiority of the six-week regimen in preventing mother-to-child HIV transmission in breast-fed infants.

International Copper Industry Defines Role In The Fight Against Hospital Infections
The copper industry is working together to answer one very important question: Can copper and copper alloys (brass and bronze) help curb the spread of bacteria that cause hospital infection? Results of laboratory testing and clinical trials indicate that they can. Scientists from around the world shared their work at the first world congress, 'Copper and Public Health', on copper's role in fighting the bacteria that cause hospital-acquired infections.

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor Of CK2
Cylene Pharmaceuticals announced that it has initiated a Phase I clinical trial of its oral CK2 protein kinase inhibitor, CX-4945, in patients with advanced solid tumors, Castleman's disease, or multiple myeloma. The primary endpoints of the oral dose escalating trial are determination of safety, tolerance and PK properties of CX-4945 and to select the appropriate dose for Phase II trials.

Phase III Trial Begins For GAMMAGARD LIQUID Plus RHuPH20 In Primary Immunodeficiency Patients
Baxter International Inc. and Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the start of a Phase III clinical trial of Baxter's GAMMAGARD LIQUID [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze(TM) Technology) for the treatment of primary immunodeficiency (PID).

Prism Pharmaceuticals Receives FDA Approval Of NEXTERONE(R) For Life Threatening Ventricular Fibrillation And Ventricular Tachycardia
Prism Pharmaceuticals announced that the U.S. Food & Drug Administration (FDA) has approved the new drug application (NDA) for NEXTERONE(R) (amiodarone HCl) Injection, a novel, patent-protected, cosolvent free formulation of the antiarrhythmic agent Amiodarone IV, originally marketed in the US by Wyeth as Cordarone(R) Intravenous.

Immutep Announces Positive Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
Immutep S.A. announced today interim results from its ongoing Phase I/II chemoimmunotherapy clinical trial in metastatic breast carcinoma. ImmuFact IMP321 was administered the day after weekly paclitaxel for six months. The interim results show a clinical response rate of 50 per cent compared to 25 per cent with paclitaxel alone. In addition, a robust immune response was observed in clinically-responding patients.

Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting
A study published today in the Journal of Clinical Oncology demonstrates that the addition of Erbitux® (cetuximab) to standard oxaliplatin-based chemotherapy (FOLFOX-4) in previously untreated metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors results in significantly higher efficacy than chemotherapy alone.

Antioxidants Offer Pain Relief In Patients With Chronic Pancreatitis
Antioxidant supplementation was found to be effective in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis (CP), reports a new study in Gastroenterology. CP is a progressive inflammatory disease of the pancreas in which patients experience abdominal pain (in early stage) and diabetes and maldigestion (in late stage).

Factors Other Than Central Sleep Apnea May Contribute To Poor Sleep Quality In Heart-Failure Patients
A study in the Jan. 1 issue of the journal Sleep demonstrates that the frequent arousals from sleep that occur in heart failure patients with central sleep apnea (CSA) may reflect the presence of another underlying arousal disorder rather than being a defensive mechanism to terminate apneas.

Study Shows Machine Perfusion Significantly Improves Transplant Results
A landmark study published in the New England Journal of Medicine (NEJM) demonstrates that use of a specially-designed machine to store kidneys for transplantation offers significant benefits in kidney survival and function when compared to those stored in a traditional "ice box", or cold storage.

Novartis Strengthens Vaccine Pipeline With Agreement For Novel CMV Vaccines Candidate
Novartis has strengthened its vaccines pipeline through an exclusive agreement to license AlphaVax' investigational Cytomegalovirus (CMV) vaccine program. This CMV agreement adds to Novartis' promising early stage pipeline of novel vaccines, which focuses on significant unmet needs for the prevention of fatal diseases such as meningococcal infections and other hospital and community acquired infections.

Can-Fite Completed Patient Enrollment For The Confirmatory Phase IIb Trial In Rheumatoid Arthritis Patients With CF101
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 230 patients in its confirmatory phase IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into 3 groups treated with 0.1 mg and 4 mg of CF101, and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 30 sites in Europe and Israel.

Andromeda Biotech Announces Successful Phase III Interim Results Of Its Lead Product, DiaPep277 For Type 1 Diabetes
Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (CBI), focused on the development of innovative treatment for autoimmune diabetes announces positive results following the Phase III interim analysis for the company's lead product, DiaPep277 for the treatment of Type 1 diabetes.

Preventive Antibiotic Use Reduced ICU Deaths
Researchers studying nearly 6,000 patients in intensive care units (ICUs) in 13 hospitals throughout the Netherlands, found that giving antibiotics as a preventive measure to ICU patients increased their chances of survival. The study was the work of first author Dr.

Prevention Of Organ Rejection In Stable Kidney Transplant Patients - LCP-Tacroâ„¢ Moves Into Clinical Phase 3
LifeCycle Pharma A/S (OMX:LCP) today announced the enrollment of the first patient in it's Phase 3 clinical trial program for use of LCP-Tacroâ„¢ in the prevention of organ rejection in stable kidney transplant patients. The clinical trial protocol has been reviewed by FDA, and LCP expects to enroll approximately 300 stable kidney transplant patients in the program. The study will be conducted at approximately 50 sites in U.S.